Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has signed a contract with the CEVA Animal Health group to develop a hormonal device for the veterinary market. CEVA Animal Health is one of the ten largest veterinary pharmaceutical groups in the world and develops products that meet the specific needs of the various sectors of this market, particularly bovines.
With this first veterinarian project in development, Mithra will develop a hormonal device for the bovine fertility market. This polymer-based device would be a real innovation in a very limited competitive market where the vaginal ring is mainly used. Feasibility studies will begin in the first half of 2019 and will aim to produce prototypes.
This project will expand Mithra’s R&D capability in polymer based drug development, moving into new polymeric forms and the veterinarian market. Furthermore, this project illustrates the wide range of development opportunities of polymer technologies and, in addition, confirms Mithra’s strong experience in this field (with the contraceptive vaginal ring Myring™ and the hormonal subcutaneous implant Zoreline®).
François Fornieri, CEO Mithra Women’s Health, commented: “We are very pleased with this first development project for a leading veterinary company. This project expands Mithra’s capability in polymer technology and confirms our R&D expertise in this field. Furthermore, it highlights the great business opportunity this technology represents across the pharmaceutical and the veterinary market, in addition to generating revenues. In a constant effort to expand our areas of activity and to sustain market demand, we have already strengthened our R&D team and will continue to do so in the coming months.”
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com